Results 51 to 60 of about 48,841 (237)

Sclerosing Cholangitis: Clinicopathologic Features, Imaging Spectrum, and Systemic Approach to Differential Diagnosis [PDF]

open access: yes, 2017
Sclerosing cholangitis is a spectrum of chronic progressive cholestatic liver disease characterized by inflammation, fibrosis, and stricture of the bile ducts, which can be classified as primary and secondary sclerosing cholangitis.
서니은
core   +1 more source

Bio‐Memristor Based on Clinical Bile Samples: A Proof‐of‐Concept Pilot Study for Detection of Gallbladder Cancer

open access: yesAdvanced Science, EarlyView.
In this work, we present a bile‐based memristor hardware framework that enables direct, label‐free identification of cholelithiasis and gallbladder cancer at the device level. The Ag/bile/FTO memristor features stable resistive switching and disease‐specific electrical responses, providing a conceptual foundation for circuits and an integrated ERCP ...
Junming Zhu   +17 more
wiley   +1 more source

Sclerosing cholangitis in the paediatric patient

open access: yes, 2001
Sclerosing cholangitis in childhood is a heterogeneous condition, which has different aetiologies. Sclerosing cholangitis may be inherited and diagnosed in the neonatal period (neonatal sclerosing cholangitis); it may present later with features of ...
Vergani, D   +3 more
core   +1 more source

Evaluation of the effectiveness of treatment of primary sclerosing cholangitis and autoimmune sclerosing cholangitis in children and adolescents

open access: yesMedičnì Perspektivi
Primary sclerosing cholangitis and autoimmune sclerosing cholangitis in children are rare chronic liver diseases characterized by progressive bile duct damage, fibrogenesis, and a risk of developing biliary cirrhosis. Autoimmune sclerosing cholangitis is
M.B. Dyba   +3 more
doaj   +1 more source

Translational Macrophage Mechano‐Immunotherapy for Next‐Generation Implantable Biomaterials

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review explores how macrophage mechanosensing drives inflammation, fibrosis and foreign body responses to implanted biomaterials. It examines emerging pharmacological strategies to modulate mechanotransduction, alongside biomaterial platforms for localised drug delivery, clinical translation, regulatory considerations and standardised testing ...
Xueying Xu, Ian L. Chin, Richard P. Tan
wiley   +1 more source

Secondary Sclerosing Cholangitis and Hodgkin's Lymphoma

open access: yes, 2015
Context Liver damage is relatively common in patients affected by HL, but paraneoplastic cholestasis is an uncommon presenting symptom in HL. Case Report We report the case of a 38-year-old man who came to our hospital with jaundice, pruritis, nausea ...
Seyed Hassan Abedi   +4 more
core   +1 more source

Clinical Features, Differential Diagnosis and Treatment of IgG4-Related Sclerosing Cholangitis

open access: yesАрхивъ внутренней медицины
The aim: To present the state-of-the-art of clinical features, differential diagnosis and treatment of IgG4-related sclerosing cholangitis.Key points: IgG4-sclerosing cholangitis is a fibrotic inflammatory disease affecting the intrahepatic and ...
A. K. Guseva, A. V. Okhlobystin
doaj   +1 more source

A Gentleman with Anemia and Cholestasis

open access: yesCase Reports in Medicine, 2010
Primary sclerosing cholangitis is a rare cause of cholestasis caused by progressive inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts leading to multifocal ductal strictures.
Siu-Tong Law   +3 more
doaj   +1 more source

Sump syndrome of the remnant common bile duct following a living donor liver transplant

open access: yesJournal of Community Hospital Internal Medicine Perspectives, 2021
Sump syndrome – a collection of digested food, debris, stones, bile, and bacteria in a poorly drained, bile duct reservoir – occurs most commonly after a side-to-side choledochoduodenostomy.
Gordon Robbins   +5 more
doaj   +1 more source

Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report

open access: yesCancer Treatment and Research Communications, 2021
Atezolizumab is an immune checkpoint inhibitor that is a key drug in non-small-cell lung cancer treatment. However, it can cause immune-related adverse events, including liver injury.
Shinji Nabeshima   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy